Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4064912 · 1 trial · 2 indications
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| Part A: LY4064912 (Cohorts 1-6) | EXPERIMENTAL | LY4064912 administered subcutaneously (SC) |
| Part A: LY4064912 (Cohort 6a) | EXPERIMENTAL | LY4064912 administered intravenously (IV) |
| Part A: Placebo | PLACEBO_COMPARATOR | Placebo administered SC and IV |
| Part B: LY4064912 (Cohorts 7-10) | EXPERIMENTAL | LY4064912 administered SC |
| Part B: Placebo | PLACEBO_COMPARATOR | Placebo administered SC |
| Part C: LY4064912 (Cohort 11) | EXPERIMENTAL | LY4064912 administered SC |
| Part C: Placebo | EXPERIMENTAL | Placebo administered SC |
| Name | Type | Description |
|---|---|---|
| LY4064912 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Age is 21-65 years old at Singapore Sites * Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring Part A: Body Mass Index (BMI) within the range greater than or equal ...
LY4064912 is an investigational small molecule being developed for the treatment of overweight or obesity. It is currently in Phase 1 clinical development, with a study evaluating its effects in healthy participants and individuals with overweight or obesity.
LY4064912 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The drug is currently in Phase 1 clinical trials for overweight or obesity.
LY4064912 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials for the treatment of overweight or obesity.
LY4064912 is being studied in a Phase 1 clinical trial with the identifier NCT07152002. This trial is titled 'A Study of LY4064912 in Healthy Participants and With Overweight or Obesity' and is active but not recruiting participants.
Yes, the Phase 1 trial of LY4064912 is a randomized, double-blind, placebo-controlled study. It is designed to evaluate the drug in healthy participants and those with overweight or obesity, with an enrollment of 144 participants.